PRPO icon

Precipio

5.56 USD
Updated Apr 1, 3:23 PM EDT
1 day
0.00%
5 days
-15.89%
1 month
-23.52%
3 months
3.73%
6 months
-17.14%
Year to date
3.73%
1 year
-18.71%
5 years
-59.06%
10 years
-99.88%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

11% more funds holding

Funds holding: 9 [Q3] → 10 (+1) [Q4]

0.7% more ownership

Funds ownership: 4.24% [Q3] → 4.94% (+0.7%) [Q4]

5% less capital invested

Capital invested by funds: $422K [Q3] → $402K (-$20.5K) [Q4]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for PRPO.

Financial journalist opinion

Neutral
Seeking Alpha
16 hours ago
Precipio, Inc. (PRPO) Q4 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Q4 and Year-End 2024 Shareholder Update Conference Call. All participants will be in listen-only mode.
Precipio, Inc. (PRPO) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET.
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
Neutral
GlobeNewsWire
1 month ago
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Both metrics demonstrate the ability to achieve financial independence Both metrics demonstrate the ability to achieve financial independence
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Neutral
GlobeNewsWire
2 months ago
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , announced that options granted to senior management on January 14 would vest when the 10-day VWAP of the Company's common stock exceeds $30.30 per share – a level 5x greater than the option exercise price, the closing price from Tuesday, January 14.
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
Positive
Zacks Investment Research
4 months ago
Two Smaller Companies Worthy of Your "Attention"
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
Two Smaller Companies Worthy of Your "Attention"
Neutral
Seeking Alpha
4 months ago
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call.
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Precipio Announces Q3-2024 Shareholder Update Call
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses.
Precipio Announces Q3-2024 Shareholder Update Call
Neutral
GlobeNewsWire
5 months ago
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
Neutral
GlobeNewsWire
6 months ago
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees.
Precipio Announces Employee Stock Option Plan Repricing
Positive
Zacks Investment Research
6 months ago
Zacks Initiates Coverage of Precipio With Outperform Recommendation
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.
Zacks Initiates Coverage of Precipio With Outperform Recommendation
Charts implemented using Lightweight Charts™